Title:MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance
Volume: 28
Issue: 33
Author(s): Anna Puła, Paweł Robak and Tadeusz Robak*
Affiliation:
- Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93-510 Lodz Ul, Ciolkowskiego 2,Poland
Keywords:
Bortezomib, drug resistance, epigenetics, microRNA, multiple myeloma, p53, pathogenesis, prognostic
markers.
Abstract: Multiple myeloma (MM) is a common malignant hematological malignancy.
Recently, interest has grown in the role of non-coding regions in disease pathogenesis. MicroRNAs
(miRNAs) are small non-coding RNAs containing 19-25 bases that play a crucial
role in messenger RNA silencing and post-transcriptional regulation of gene expression.
Several miRNAs demonstrate markedly dysregulated expression in MM, suggesting that
they may act as both tumor suppressors and oncogenes. microRNAs are also reportedly
involved in the regulation of other epigenetic mechanisms of gene expression. Additionally,
some miRNAs have been associated with drug resistance, and therefore a further exploration
of their activity may lead to its reversal. Moreover, miRNA expression patterns in
either MM cells or serum exosomes have been shown to be good prognostic markers. This
review describes the roles of miRNAs in MM and examines their potential to predict MM
prognosis and play a role in novel therapeutic strategies.
